Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention

Htun, Patrik, Fateh-Moghadam, Suzanne, Bischofs, Christian, Banya, Winston, Müller, Karin, Bigalke, Boris, Stellos, Konstantinos, May, Andreas E, Flather, Marcus, Gawaz, Meinrad and Geisler, Tobias (2011) Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention. Journal of the American Society of Nephrology, 22 (4). pp. 627-33. ISSN 1533-3450

Full text not available from this repository. (Request a copy)

Abstract

Patients with CKD are at higher risk for major events after percutaneous coronary intervention (PCI) compared with subjects with normal renal function. The aims of this study were to evaluate responsiveness to clopidogrel in patients with CKD and to examine the effect of antiplatelet drug response on post-PCI outcome. We retrospectively evaluated a consecutive cohort of 1567 patients with symptomatic coronary artery disease undergoing PCI, 648 (41%) of whom had stage 3 to 5 CKD. We assessed responsiveness to clopidogrel by ADP-induced platelet aggregation after oral administration of a 600-mg clopidogrel loading dose and 100 mg of aspirin. In a multivariate survival analysis that included 1335 (85%) of the cohort, stage 3 to 5 CKD and low response to clopidogrel were independent predictors of the primary end point (composite of myocardial infarction, ischemic stroke, and death within 1 year). In summary, a low response to clopidogrel might be an additional risk factor for the poorer outcomes in patients with stage 3 to 5 CKD compared with patients with better renal function.

Item Type:	Article
Additional Information:	Copyright © 2011 by the American Society of Nephrology
Uncontrolled Keywords:	aged,angioplasty, balloon, coronary,aspirin,chronic disease,cohort studies,coronary artery disease,dose-response relationship, drug,drug therapy, combination,female,hemorrhage,humans,kidney diseases,male,middle aged,platelet aggregation inhibitors,retrospective studies,risk factors,ticlopidine,treatment outcome
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Norwich Clinical Trials Unit Faculty of Medicine and Health Sciences > Research Groups > Cardiovascular and Metabolic Health Faculty of Medicine and Health Sciences > Research Groups > Public Health and Health Services Research (former - to 2023)
Depositing User:	Pure Connector
Date Deposited:	20 Jan 2014 16:12
Last Modified:	24 Oct 2022 05:35
URI:	https://ueaeprints.uea.ac.uk/id/eprint/46241
DOI:	10.1681/ASN.2010020220

Actions (login required)

View Item